+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metabolic Disorders Therapeutics Market Research Report by Disease Type (Diabetes, Hypercholesterolemia, and Lysosomal Storage Disease), Product, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 5123296
  • Report
  • April 2022
  • Region: United States
  • 119 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Abbvie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Astazeneca Plc
  • Biocon
The United States Metabolic Disorders Therapeutics Market size was estimated at USD 10.59 billion in 2021, USD 12.09 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.56% to reach USD 19.35 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Metabolic Disorders Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Disease Type, the market was studied across Diabetes, Hypercholesterolemia, Lysosomal Storage Disease, and Obesity.
  • Based on Product, the market was studied across Globoid Leukodystrophy, Hepatic Encephalopathy, and Metachromatic Leukodystrophy.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Metabolic Disorders Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Metabolic Disorders Therapeutics Market, including Abbvie, Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astazeneca Plc, Biocon, Eli Lily, Merck, Novo Nordisk, and Sanofi.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the United States Metabolic Disorders Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Metabolic Disorders Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Metabolic Disorders Therapeutics Market?
4. What is the competitive strategic window for opportunities in the United States Metabolic Disorders Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the United States Metabolic Disorders Therapeutics Market?
6. What is the market share of the leading vendors in the United States Metabolic Disorders Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the United States Metabolic Disorders Therapeutics Market?
Frequently Asked Questions about the U.S. Metabolic Disorders Therapeutics Market

What is the estimated value of the U.S. Metabolic Disorders Therapeutics Market?

The U.S. Metabolic Disorders Therapeutics Market was estimated to be valued at $10.6 Billion in 2021.

What is the growth rate of the U.S. Metabolic Disorders Therapeutics Market?

The growth rate of the U.S. Metabolic Disorders Therapeutics Market is 10.5%, with an estimated value of $19.4 Billion by 2027.

What is the forecasted size of the U.S. Metabolic Disorders Therapeutics Market?

The U.S. Metabolic Disorders Therapeutics Market is estimated to be worth $19.4 Billion by 2027.

Who are the key companies in the U.S. Metabolic Disorders Therapeutics Market?

Key companies in the U.S. Metabolic Disorders Therapeutics Market include Abbvie, Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astazeneca Plc, Biocon, Eli Lily, Merck and Sanofi.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Astazeneca Plc
  • Biocon

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Metabolic Disorders Therapeutics Market, by Disease Type
6.1. Introduction
6.2. Diabetes
6.3. Hypercholesterolemia
6.4. Lysosomal Storage Disease
6.5. Obesity
7. Metabolic Disorders Therapeutics Market, by Product
7.1. Introduction
7.2. Globoid Leukodystrophy
7.3. Hepatic Encephalopathy
7.4. Metachromatic Leukodystrophy
8. California Metabolic Disorders Therapeutics Market9. Florida Metabolic Disorders Therapeutics Market10. Illinois Metabolic Disorders Therapeutics Market11. New York Metabolic Disorders Therapeutics Market12. Ohio Metabolic Disorders Therapeutics Market13. Pennsylvania Metabolic Disorders Therapeutics Market14. Texas Metabolic Disorders Therapeutics Market
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis, By Key Player
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration, & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding
15.4.5. Award, Recognition, & Expansion
16. Company Usability Profiles
16.1. Abbvie
16.2. Actelion Pharmaceuticals
16.3. Amicus Therapeutics
16.4. Arena Pharmaceuticals
16.5. Astazeneca Plc
16.6. Biocon
16.7. Eli Lily
16.8. Merck
16.9. Novo Nordisk
16.10. Sanofi
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: DYNAMICS
FIGURE 2. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (%)
FIGURE 3. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2027
FIGURE 5. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, 2019-2027 (USD BILLION)
FIGURE 6. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 7. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, 2019-2027 (USD BILLION)
FIGURE 8. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 9. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, 2019-2027 (USD BILLION)
FIGURE 10. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 11. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, 2019-2027 (USD BILLION)
FIGURE 12. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 13. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 14. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD BILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2027
FIGURE 16. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, 2019-2027 (USD BILLION)
FIGURE 17. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 18. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, 2019-2027 (USD BILLION)
FIGURE 19. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 20. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, 2019-2027 (USD BILLION)
FIGURE 21. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 22. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 23. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 24. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET, BY TYPE
List of Tables
TABLE 1. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD BILLION)
TABLE 4. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY STATE, 2019-2027 (USD BILLION)
TABLE 5. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY STATE, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY STATE, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 9. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY STATE, 2019-2027 (USD BILLION)
TABLE 10. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY STATE, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: SCORES
TABLE 13. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 14. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 15. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: RANKING
TABLE 16. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 17. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 18. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 19. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 20. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 21. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 22. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbvie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Astazeneca Plc
  • Biocon
  • Eli Lily
  • Merck
  • Novo Nordisk
  • Sanofi
Note: Product cover images may vary from those shown

Loading
LOADING...